Wanbury growth over the years

·Pharma & HealthChart ›
ProfitabilityGrowthCreditLiquidityWorking capitalDividend yieldDuPontCAGR
Compounded a year1 yr3 yr
Revenue+8.5%+9.2%
EBITDA+39.9%+66.4%
Net Income+116.7%—
EPS (adj.)+116.7%—
Total Assets+25.1%+19.6%
Total Equity+143.9%—
Open the chart

From the company's filings with NSE and BSE (Ind-AS), standalone. For information only, not investment advice.

WANBURY₹174.16

Wanbury Limited

· Pharma & Health
₹ CrorePeersAHCLANUHPHRBAJAJHCARETHEMISMEDZIMLABLINCOLNSIGACHIVALIANTLABMcap ₹609 Cr
Annuals · FY-end closes
Compounded Growth
Annuals · CAGR %
1Y
CAGR
3Y
CAGR
Revenue+8.5+9.2
EBITDA+39.9+66.4
Net Income+116.7—
EPS (adj.)+116.7—
Total Assets+25.1+19.6
Total Equity+143.9—
CAGR from filed annuals — needs positive start & end values.
« ‹ › »Latest: FY26 · StandaloneFA Financial Analysis · alphave
Data & compliance. Descriptive financial information from official NSE/BSE filings — for information and education only, not investment advice, a recommendation, or a valuation. Standalone = parent entity; consolidated includes subsidiaries. Historical multiples pair each fiscal year's filed figures with that FY-end market close; the Current column uses the last close with the latest filed annuals. Figures are cross-verified via accounting identities and NSE×BSE agreement — XBRL cross-verified ✓ 95%.